Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)
Stopped Sponsor decision to prematurely stop the study, not linked to any safety concern.
Conditions
Interventions
- DRUG: Amcenestrant (SAR439859)
Sponsor
Sanofi